A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection (Q35933501)

11 August 2017

title

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection (English)

1 reference

11 August 2017

0 references

Clostridium difficile

0 references

1 reference

1 reference

4

Colleen S Kraft

1 reference

11 August 2017

13

Roger J Pomerantz

1 reference

11 August 2017

Sahil Khanna

1

1 reference

11 August 2017

Darrell S Pardi

2

1 reference

11 August 2017

Colleen R Kelly

3

1 reference

11 August 2017

Tanvi Dhere

5

1 reference

11 August 2017

Matthew R Henn

6

1 reference

11 August 2017

Mary-Jane Lombardo

7

1 reference

11 August 2017

Marin Vulic

8

1 reference

11 August 2017

Toshiro Ohsumi

9

1 reference

11 August 2017

Jonathan Winkler

10

1 reference

11 August 2017

Christina Pindar

11

1 reference

11 August 2017

Barbara H McGovern

12

1 reference

11 August 2017

John G Aunins

14

1 reference

11 August 2017

David N Cook

15

1 reference

11 August 2017

Elizabeth L Hohmann

16

1 reference

11 August 2017

language of work or name

English

0 references

publication date

8 February 2016

1 reference

Journal of Infectious Diseases

11 August 2017

published in

1 reference

11 August 2017

volume

214

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

173-181

1 reference

Burden of Clostridium difficile infection in the United States

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Control of pathogens and pathobionts by the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Clostridium difficile--more difficult than ever

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Disruption of the gut microbiome as a risk factor for microbial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

New drugs and strategies for management of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Clostridium difficile Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Structure, function and diversity of the healthy human microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

The human microbiome project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

A human gut microbial gene catalogue established by metagenomic sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Richness of human gut microbiome correlates with metabolic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

What is the value of a food and drug administration investigational new drug application for fecal microbiota transplantation to treat Clostridium difficile Infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Toward a true bacteriotherapy for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Treating Clostridium difficile infection with fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

A question of clarity: redesigning the American Association Of Blood Banks blood donor history questionnaire--a chronology and model for donor screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Fecal microbiota transplantation in relapsing Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Antibiotic-Induced Alterations of the Murine Gut Microbiota and Subsequent Effects on Colonization Resistance against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Biodiversity and ecosystem productivity in a fluctuating environment: the insurance hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Endotoxicity of lipopolysaccharide as a determinant of T-cell-mediated colitis induction in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Weight gain after fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Burden of Clostridium difficile on the healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Economic healthcare costs of Clostridium difficile infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV766

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIV766

1 reference

11 August 2017

1 reference